Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma - 11/09/11
From the U.S. Army Medical Research Institute for Chemical Defense, Aberdeena; Walter Reed Army Institute of Researchb; Armed Forces Institute of Research, Department of Dermatopathologyc; and the Henry M. Jackson Foundation,d Bethesda, Md.
Abstract |
Background: Although intralesional vinblastine has been used with some success in the treatment of cutaneous lesions of Kaposi's sarcoma (KS), lesions commonly recur. When large lesions are treated, frequently there is considerable discomfort and, in some cases, secondary ulceration. Hyaluronidase has been used to increase dispersion of drugs administered by local injection.
Objective: Our purpose was to determine whether intralesional hyaluronidase administered before intralesional vinblastine increases the dispersion of vinblastine and decreases toxicity.
Methods: We treated six patients who had multiple cutaneous plaque lesions and tumors of KS with intralesional vinblastine, intralesional vinblastine preceded by intralesional hyaluronidase, or intralesional hyaluronidase alone.
Results: Both intralesional vinblastine and intralesional vinblastine preceded by intralesional hyaluronidase caused clinical regression of lesions of KS; however, the combination of hyaluronidase and vinblastine was more effective in treating tumor nodules. In addition, lesions treated with hyaluronidase and vinblastine recurred less often than those treated with vinblastine alone and showed no evidence of residual KS in two patients undergoing biopsy between 4 and 6 months after therapy.
Conclusion: Intralesional hyaluronidase enhances vinblastine in the treatment of cutaneous lesions of KS without adding to the systemic toxicity.
(J Am Acad Dermatol 1997;36:239-42.)
Le texte complet de cet article est disponible en PDF.Plan
 | The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army, the Department of the Navy, or the Department of Defense. |
| Reprint requests: Henry G. Skelton, MD, Department of Dermatopathology, Armed Forces Institute of Pathology, Washington, DC 20306. |
 | 16/1/76712 |
Vol 36 - N° 2
P. 239-242 - février 1997 Retour au numéro
Article précédent
- Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin
- Christian A. Sander, Christiane Pfeiffer, Albert M. Kligman, Gerd Plewig, From the Department of Dermatology, Ludwig-Maximilians-Universitaet, Municha; and the Department of Dermatology, University of Pennsylvania, School of Medicine, Philadelphia.b
- Insect repellents: An overview
- Margaret Brown, Adelaide A. Hebert, From the Departments of Dermatologya and Pediatrics,b The University of Texas Medical School at Houston.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?